Methylation profile of the promoter region of IRF5 in primary Sjögren's syndrome

European Cytokine Network

Volumn 23, Issue 4, 2012, Pages 166-172

  Gestermann, Nicolas ^a   Koutero, Mikael ^b   Belkhir, Rakiba ^a   Tost, Jörg ^b,c   Mariette, Xavier ^d   Miceli Richard, Corinne ^d  

^a INSERM   (France)

^b CENTRE NATIONAL DE GÉNOTYPAGE   (France)

^c FONDATION JEAN DAUSSET CEPH   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Autoimmune diseases; DNA methylation; Epigenetics; IRF5; Sj gren's syndrome

Indexed keywords

CD4 ANTIGEN; INTERFERON REGULATORY FACTOR 5;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETIC REPRESSION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOCYTE; PROMOTER REGION; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SJOEGREN SYNDROME; T LYMPHOCYTE;

AUTOIMMUNE DISEASES; DNA METHYLATION; EPIGENETICS; IRF5; SJÖGREN'S SYNDROME;

ADULT; AZACITIDINE; CD4-POSITIVE T-LYMPHOCYTES; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION; HUMANS; INTERFERON REGULATORY FACTORS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SJOGREN'S SYNDROME;

EID: 84873703760     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2012.0316     Document Type: Article

References (30)

1. Cooper GS, Bynum ML, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun 2009; 33: 197-207.
2. Bowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR. Estimating the prevalence among Caucasian women of primary Sjogren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 2004; 33: 39-43.
3. Chused TM, Kassan SS, Opelz G, Moutsopoulos HM, Terasaki PI. Sjogren's syndrome association with HLA-Dw3. N Engl J Med 1977; 296: 895-7.
4. Kang HI, Fei HM, Saito I, et al. Comparison of HLA class II genes in Caucasoid, Chinese, and Japanese patients with primary Sjogren's syndrome. J Immunol 1993; 150: 3615-23.
5. Gottenberg JE, Cagnard N, Lucchesi C, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci U S A 2006; 103: 2770-5.
6. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005; 52: 1534-44.
7. Miceli-Richard C, Comets E, Loiseau P, Puechal X, Hachulla E, Mariette X. Association of an IRF5 gene functional polymorphism with Sjogren's syndrome. Arthritis Rheum 2007; 56: 3989-94.
8. Miceli-Richard C, Gestermann N, Ittah M, et al. The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjogren's syndrome. Arthritis Rheum 2009; 60: 1991-7.
9. Barnes BJ, Moore PA, Pitha PM. Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes. J Biol Chem 2001; 276: 23382-90.
10. Nordmark G, Kristjansdottir G, Theander E, et al. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjogren's syndrome. Genes Immun 2009; 10: 68-76.
11. Dideberg V, Kristjansdottir G, Milani L, et al. An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet 2007; 16: 3008-16.
12. Sigurdsson S, Goring HH, Kristjansdottir G, et al. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum Mol Genet 2008; 17: 872-81.
13. Lu Q, Wu A, Tesmer L, Ray D, Yousif N, Richardson B. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol 2007; 179: 6352-8.
14. Lu Q, Wu A, Richardson BC. Demethylation of the same promoter sequence increases CD70 expression in lupus T cells and T cells treated with lupus-inducing drugs. J Immunol 2005; 174: 6212-9.
15. Shin SH, Kim BH, Jang JJ, Suh KS, Kang GH. Identification of novel methylation markers in hepatocellular carcinoma using a methylation array. J Korean Med Sci 2010; 25: 1152-9.
16. Lu R, Au WC, Yeow WS, Hageman N, Pitha PM. Regulation of the promoter activity of interferon regulatory factor-7 gene. Activation by interferon and silencing by hypermethylation. J Biol Chem 2000; 275: 31805-12.
17. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
18. Dimitriou ID, Kapsogeorgou EK, Abu-Helu RF, Moutsopoulos HM, Manoussakis MN. Establishment of a convenient system for the long-term culture and study of non-neoplastic human salivary gland epithelial cells. Eur J Oral Sci 2002; 110: 21-30.
19. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nat Protoc 2007; 2: 2265-75.
20. Savitsky DA, Yanai H, Tamura T, Taniguchi T, Honda K. Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus. Proc Natl Acad Sci U S A 2010; 107: 10154-9.
21. Lien C, Fang CM, Huso D, Livak F, Lu R, Pitha PM. Critical role of IRF-5 in regulation of B-cell differentiation. Proc Natl Acad Sci U S A 2010; 107: 4664-8.
22. Yasuda K, Richez C, Maciaszek JW, et al. Murine dendritic cell type I IFN production induced by human IgG-RNA immune complexes is IFN regulatory factor (IRF)5 and IRF7 dependent and is required for IL-6 production. J Immunol 2007; 178: 6876-85.
23. Krausgruber T, Blazek K, Smallie T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011; 12: 231-8.
24. Jarvinen TM, Hellquist A, Koskenmies S, et al. Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus. Exp Dermatol 2010; 19: 123-31.
25. Kristjansdottir G, Sandling JK, Bonetti A, et al. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J Med Genet 2008; 45: 362-9.
26. Sigurdsson S, Padyukov L, Kurreeman FA, et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum 2007; 56: 2202-10.
27. Balasa A, Gathungu G, Kisfali P, et al. Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases. Int J Colorectal Dis 2010; 25: 553-6.
28. Stagakis E, Bertsias G, Verginis P, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis 2011; 70: 1496-506.
29. Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 2009; 60: 1065-75.
30. Jeffries MA, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics 2011; 6: 593-601.